MicroVAX is a clinical stage biotech company dedicated to the development of potent vaccines, for treatment and prevention of cancer and infectious diseases.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
MicroVAX proprietary vaccine platform is created by attaching the target-associated antigen (TAA) for the vaccine to the extracellular domain (ecd) of the potent immunostimulatory signal CD40 ligand (CD40L). Attachment of the TAA to the CD40L promotes uptake of the TAA into dendritic cells (DCs), binding to Class I as well as Class II MHC leading to presentation of the TAA on the DCs, expansion of the TAA-specific B cell and CD8 effector T-cell lymphocytes, and induction of a memory response.
MicroVAXs vaccine clinical trial is sponsored by the Singapore Clinical Research Institute (SCRI) and obtained a research grant for SGD $800,000 from National Medical Research Council, Singapore for support of the evaluation of the immune response induced by the vaccination of subjects in the clinical trial.